Enanta Pharmaceuticals ENTA has observed the following analyst ratings within the last quarter:

These 7 analysts have an average price target of $68.29 versus the current price of Enanta Pharmaceuticals at 71.65, implying downside.

Below is a summary of how these 7 analysts rated Enanta Pharmaceuticals over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the move negative analysts are on the stock

This average price target has increased by 11.95% over the past month.

How Are Analyst Ratings Determined?

Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.